KD Logo

Collegium Pharmaceutical Inc (COLL) receives a Buy rating from Jefferies

Collegium Pharmaceutical Inc’s recently made public that its EVP and General Counsel Kuhlmann Shirley R. unloaded Company’s shares for reported $0.81 million on Jun 03 ’24. In the deal valued at $32.57 per share,25,000 shares were sold. As a result of this transaction, Kuhlmann Shirley R. now holds 139,409 shares worth roughly $4.41 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Tupper Colleen sold 19,710 shares, generating $674,368 in total proceeds. Upon selling the shares at $34.21, the EVP & Chief Financial Officer now owns 130,845 shares.

Before that, Dreyer Scott sold 56,807 shares. Collegium Pharmaceutical Inc shares valued at $1,930,455 were divested by the EVP & Chief Commercial Officer at a price of $33.98 per share. As a result of the transaction, Dreyer Scott now holds 105,902 shares, worth roughly $3.35 million.

Jefferies upgraded its Collegium Pharmaceutical Inc [COLL] rating to a Buy from a a Hold in a research note published on June 07, 2024; the price target was increased to $44 from $41. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who decreased its forecast for the stock in early May from “an Overweight” to “a Neutral”. Needham also remained covering COLL and has decreased its forecast on May 10, 2024 with a “Hold” recommendation from previously “Buy” rating. Jefferies revised its rating on January 04, 2024. It rated COLL as “a Hold” which previously was an “a Buy”.

Price Performance Review of COLL

On Tuesday, Collegium Pharmaceutical Inc [NASDAQ:COLL] saw its stock fall -0.75% to $31.66. Over the last five days, the stock has lost -2.94%. Collegium Pharmaceutical Inc shares have risen nearly 2.86% since the year began. Nevertheless, the stocks have risen 45.63% over the past one year. While a 52-week high of $40.95 was reached on 03/28/24, a 52-week low of $20.95 was recorded on 05/10/24. SMA at 50 days reached $33.51, while 200 days put it at $31.23. A total of 0.3 million shares were traded, compared to the trading of 0.33 million shares in the previous session.

Levels Of Support And Resistance For COLL Stock

The 24-hour chart illustrates a support level at 31.25, which if violated will result in even more drops to 30.84. On the upside, there is a resistance level at 32.45. A further resistance level may holdings at 33.24. The Relative Strength Index (RSI) on the 14-day chart is 42.79, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.07, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 73.59%. Stochastics%K at 38.79% indicates the stock is a holding.

The most recent change occurred on August 25, 2023 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $36.

Most Popular